Expanded Indications for Neoadjuvant Endocrine Therapy in Early-Stage Breast Cancer During the COVID-19 Pandemic
During the COVID-19 pandemic, expanded utilization of neoadjuvant therapy for surgical breast cancer patients was observed. Health care system limitations during the pandemic contributed to expanded adoption of neoadjuvant therapy for early breast cancer, contrary to usual practice. Long-term outcomes for patients treated according to PBCC recommendations should be closely monitored.
Authors
- Rhami Khorfan (ORCID: https://orcid.org/0000-0002-0440-493X)
- Naveenraj L. Solomon (ORCID: https://orcid.org/0000-0003-2164-2312)
- Jukes P. Namm (ORCID: https://orcid.org/0000-0003-0953-8344)
- Sharon S. Lum (ORCID: https://orcid.org/0000-0001-5097-9032)
- Halley Vora
Institutions
- Loma Linda University (US)
- Loma Linda University Health Care (US)
Publication Details
- Journal
- Annals of Surgical Oncology
- Published
- 2024-08-12
- DOI
- https://doi.org/10.1245/s10434-024-15787-8
- Citations
- 4
- Primary Topic
- COVID-19 and healthcare impacts
- Type
- article
- Field-Weighted Citation Impact
- 1.13
Funders
- Foundation for the National Institutes of Health
- Breast Cancer Research Foundation
- V Foundation for Cancer Research
- American Surgical Association Foundation
- Patient-Centered Outcomes Research Institute
- American Society of Clinical Oncology
- Loma Linda University
- Florida Breast Cancer Foundation
- NIH Clinical Center